Charles E. Geyer
Impact in
- Cancer Research top 0.05%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Oncology top 0.1%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
Papers in
- Oncology 114
- HER2/EGFR in Cancer Research 64
- Cancer Treatment and Pharmacology 51
- Colorectal Cancer Treatments and Studies 11
- PARP inhibition in cancer therapy 10
-
- Breast Cancer Treatment Studies 79
- Cancer Genomics and Diagnostics 9
- Co-authors
- Norman Wolmark (112 shared papers)Eleftherios P. Mamounas (77 shared papers)Soonmyung Paik (36 shared papers)D. Lawrence Wickerham (19 shared papers)Joseph P. Costantino (39 shared papers)Priya Rastogi (80 shared papers)Stewart Anderson (19 shared papers)Jong‐Hyeon Jeong (22 shared papers)
- Journals
- Journal of Clinical Oncology (77 papers)Cancer Research (14 papers)Annals of Oncology (9 papers)Breast Cancer Research and Treatment (8 papers)Clinical Cancer Research (7 papers)
- Partner nations
- United StatesCanadaGermany
In The Last Decade
Charles E. Geyer
181 papers receiving 16.0k citations
Charles E. Geyer's Hit Papers
Peers
Comparison fields: 5 of 135
- Cancer Research 7.3k
- Oncology 8.3k
- Radiology, Nuclear Medicine and Imaging 2.2k
- Pathology and Forensic Medicine 1.4k
- Pulmonary and Respiratory Medicine 2.3k
Countries citing papers authored by Charles E. Geyer
This map shows the geographic impact of Charles E. Geyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles E. Geyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles E. Geyer more than expected).
Fields of papers citing papers by Charles E. Geyer
This network shows the impact of papers produced by Charles E. Geyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles E. Geyer. The network helps show where Charles E. Geyer may publish in the future.
Co-authors
The 25 scholars most cited alongside Charles E. Geyer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 185 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer Hit paper breakdown → | 2006 | 2514 |
| 2 | Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer Hit paper breakdown → | 2006 | 1880 |
| 3 | Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27 Hit paper breakdown → | 2008 | 1331 |
| 4 | Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27 Hit paper breakdown → | 2006 | 722 |
| 5 | Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831 Hit paper breakdown → | 2014 | 688 |
| 6 | Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: NSABP B-31 Hit paper breakdown → | 2005 | 571 |
| 7 | Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31 Hit paper breakdown → | 2011 | 540 |
| 8 | Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial Hit paper breakdown → | 2018 | 537 |
| 9 | 2010 | 409 | |
| 10 | 2012 | 402 | |
| 11 | 2006 | 348 | |
| 12 | 2009 | 331 | |
| 13 | 2012 | 320 | |
| 14 | 2019 | 288 | |
| 15 | 2013 | 263 | |
| 16 | 1995 | 261 | |
| 17 | 2012 | 244 | |
| 18 | 2008 | 239 | |
| 19 | 2010 | 230 | |
| 20 | 2010 | 229 |
About Charles E. Geyer
Charles E. Geyer is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Genetics and Radiology, Nuclear Medicine and Imaging, having authored 185 papers that have together received 16.4k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (79 papers), HER2/EGFR in Cancer Research (64 papers), Cancer Treatment and Pharmacology (51 papers), Advanced Breast Cancer Therapies (37 papers), Estrogen and related hormone effects (18 papers), Colorectal Cancer Treatments and Studies (11 papers), PARP inhibition in cancer therapy (10 papers) and Cancer Genomics and Diagnostics (9 papers). The work is most often cited by research in Cancer Research (7.3k citations), Oncology (8.3k citations), Radiology, Nuclear Medicine and Imaging (2.2k citations), Pathology and Forensic Medicine (1.4k citations) and Pulmonary and Respiratory Medicine (2.3k citations). Charles E. Geyer has collaborated with scholars based in United States, Canada and Germany. Frequent co-authors include Norman Wolmark, Eleftherios P. Mamounas, Soonmyung Paik, D. Lawrence Wickerham, Joseph P. Costantino, Priya Rastogi, Stewart Anderson, Jong‐Hyeon Jeong, Gong Tang and Sandra M. Swain. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Annals of Oncology, Breast Cancer Research and Treatment and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.